These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 37244385)

  • 1. Gut mycobiome and metabolic diseases: The known, the unknown, and the future.
    Wang L; Zhang K; Zeng Y; Luo Y; Peng J; Zhang J; Kuang T; Fan G
    Pharmacol Res; 2023 Jul; 193():106807. PubMed ID: 37244385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut mycobiome in metabolic diseases: Mechanisms and clinical implication.
    Zhou X; Zhang X; Yu J
    Biomed J; 2024 Jun; 47(3):100625. PubMed ID: 37364760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fecal mycobiome in non-alcoholic fatty liver disease.
    Demir M; Lang S; Hartmann P; Duan Y; Martin A; Miyamoto Y; Bondareva M; Zhang X; Wang Y; Kasper P; Bang C; Roderburg C; Tacke F; Steffen HM; Goeser T; Kruglov A; Eckmann L; Stärkel P; Fouts DE; Schnabl B
    J Hepatol; 2022 Apr; 76(4):788-799. PubMed ID: 34896404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the human oral and gut fungal microbiota in patients with metabolic dysfunction-associated fatty liver disease.
    Niu C; Tu Y; Jin Q; Chen Z; Yuan K; Wang M; Zhang P; Luo J; Li H; Yang Y; Liu X; Mao M; Dong T; Tan W; Hu X; Pan Y; Hou L; Ma R; Huang Z
    Front Cell Infect Microbiol; 2023; 13():1157368. PubMed ID: 37180439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host Factors Associated with Gut Mycobiome Structure.
    Szóstak N; Handschuh L; Samelak-Czajka A; Tomela K; Schmidt M; Pruss Ł; Milanowska-Zabel K; Kozlowski P; Philips A
    mSystems; 2023 Apr; 8(2):e0098622. PubMed ID: 36786595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roles for the mycobiome in liver disease.
    Zeng S; Schnabl B
    Liver Int; 2022 Apr; 42(4):729-741. PubMed ID: 34995410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gut mycobiome of the Human Microbiome Project healthy cohort.
    Nash AK; Auchtung TA; Wong MC; Smith DP; Gesell JR; Ross MC; Stewart CJ; Metcalf GA; Muzny DM; Gibbs RA; Ajami NJ; Petrosino JF
    Microbiome; 2017 Nov; 5(1):153. PubMed ID: 29178920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut mycobiome alterations in obesity in geographically different regions.
    Zhan H; Wan Y; Sun Y; Xu Z; Zhang F; Yang K; Zhu W; Cheung CP; Tang W; Ng EK; Wong SK; Yeoh YK; Kl Chan F; Miao Y; Zuo T; Zeng Z; Ng SC
    Gut Microbes; 2024; 16(1):2367297. PubMed ID: 38899956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The emerging role of the gut mycobiome in liver diseases.
    Szóstak N; Figlerowicz M; Philips A
    Gut Microbes; 2023; 15(1):2211922. PubMed ID: 37184158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease.
    Viebahn G; Hartmann P; Lang S; Demir M; Zhang X; Fouts DE; Stärkel P; Schnabl B
    Gut Microbes; 2024; 16(1):2307586. PubMed ID: 38298161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
    Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
    J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in the Gut Fungal Community in a Mouse Model of Huntington's Disease.
    Kong G; Lê Cao KA; Hannan AJ
    Microbiol Spectr; 2022 Apr; 10(2):e0219221. PubMed ID: 35262396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
    Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
    Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Could gut mycobiome play a role in NAFLD pathogenesis? Insights and therapeutic perspectives.
    Fotis D; Liu J; Dalamaga M
    Metabol Open; 2022 Jun; 14():100178. PubMed ID: 35308892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycobiome in the Gut: A Multiperspective Review.
    Chin VK; Yong VC; Chong PP; Amin Nordin S; Basir R; Abdullah M
    Mediators Inflamm; 2020; 2020():9560684. PubMed ID: 32322167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping the human gut mycobiome in middle-aged and elderly adults: multiomics insights and implications for host metabolic health.
    Shuai M; Fu Y; Zhong HL; Gou W; Jiang Z; Liang Y; Miao Z; Xu JJ; Huynh T; Wahlqvist ML; Chen YM; Zheng JS
    Gut; 2022 Sep; 71(9):1812-1820. PubMed ID: 35017200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly.
    Zhang F; Aschenbrenner D; Yoo JY; Zuo T
    Lancet Microbe; 2022 Dec; 3(12):e969-e983. PubMed ID: 36182668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic foot exacerbates gut mycobiome dysbiosis in adult patients with type 2 diabetes mellitus: revealing diagnostic markers.
    Cai Y; Li Y; Xiong Y; Geng X; Kang Y; Yang Y
    Nutr Diabetes; 2024 Sep; 14(1):71. PubMed ID: 39223127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Exogenous Hydrogen Sulfide on Diabetic Metabolic Disorders in db/db Mice Are Associated With Gut Bacterial and Fungal Microbiota.
    Liu J; Zhao W; Gao ZW; Liu N; Zhang WH; Ling H
    Front Cell Infect Microbiol; 2022; 12():801331. PubMed ID: 35425717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gut mycobiome: a novel player in chronic liver diseases.
    Jiang L; Stärkel P; Fan JG; Fouts DE; Bacher P; Schnabl B
    J Gastroenterol; 2021 Jan; 56(1):1-11. PubMed ID: 33151407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.